Eisai Co Ltd
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there are […]
Read More
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
Research at Biogen Source: Biogen Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The Japanese drugmaker and its partner Biogen last week released an additional analysis of clinical trials of the monoclonal antibody drug, which is also known as lecanemab. Alzheimer’s disease continued to progress at a slower rate […]
Read More
Eli Lilly says experimental Alzheimer’s drug reduces brain plaque in early study
Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. Jakub Porzycki | Nurphoto | Getty Images Eli Lilly‘s experimental Alzheimer’s drug lowered levels of brain plaque in patients who are in the earliest […]
Read More
Veterans Health Administration will cover Alzheimer’s treatment Leqembi, Eisai says
The Veterans Health Administration will cover Eisai and Biogen‘s Alzheimer’s treatment Leqembi, the companies announced Monday. In a statement, drugmaker Eisai said veterans in the early stages of the disease who meet VHA criteria are eligible for coverage of Leqembi. The decision by VHA stands in contrast with Medicare, which has declined to cover the […]
Read More
FDA will review Eisai’s and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July
Andrew Brookes | Image Source | Getty Images The Food and Drug Administration will make a decision on whether to fully approve Eisai‘s and Biogen‘s Alzheimer’s treatment Leqembi by July 6, the companies announced on Monday. Leqembi is an antibody treatment that targets brain plaque associated with the mind-robbing disease. It is administered intravenously twice […]
Read More
Medicare rejects Alzheimer’s Association request for unrestricted coverage of treatments like Leqembi
Medicare will not provide broader coverage of the Alzheimer’s drug Leqembi until it receives more evidence that the treatment is reasonable and necessary, according to the federal agency that runs the program for seniors. The Centers for Medicare and Medicaid Services rejected a request from the Alzheimer’s Association for unrestricted coverage of antibody treatments approved […]
Read More
Senators call on Medicare to offer broad coverage of Alzheimer’s treatments as public pressure grows
U.S. senators on Friday called for Medicare to offer broad coverage of Alzheimer’s treatments approved by the Food and Drug Administration, warning that current restrictions cost patients precious time as their disease progresses. “Given the progressive nature of this terminal disease, we encourage you to take steps now to ensure patients have immediate access to […]
Read More
Maker of promising Alzheimer’s drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
Tek Image/science Photo Library | Science Photo Library | Getty Images Japanese drugmaker Eisai expects the Food and Drug Administration to fully approve its Alzheimer’s treatment Leqembi this summer, which would expand access to the pricey new antibody under Medicare. U.S. CEO Ivan Cheung said the FDA, which granted accelerated clearance in January, could give […]
Read More
Here’s where to look for the next developments in the fight against Alzheimer’s disease
Biogen and its partner, Japanese drugmaker Eisai , earlier this month received accelerated approval from the Food and Drug Administration for Leqembi, a monoclonal antibody to treat Alzheimer’s disease. Although Biogen shares are trading higher in the wake of this development , they are only up 4% or so year to date. To some degree, […]
Read More
Fda approves Alzheimer’s drug that slowed cognitive decrease in medical demo
MRI picture of mind showing region of Alzheimer affected individual. Getty Illustrations or photos The Food items and Drug Administration on Friday granted accelerated approval for the Alzheimer’s drug lecanemab, formulated by Biogen and the Japanese pharmaceutical firm Eisai. The FDA’s approval will come immediately after scientific trial benefits published in November indicated that lecanemab […]
Read More